Literature DB >> 16230129

Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?

Cindy L Amundsen1, Audrey A Romero, Margaret G Jamison, George D Webster.   

Abstract

OBJECTIVES: To determine the variables that affect the cure rate in patients with urge incontinence treated with sacral neuromodulation.
METHODS: This prospective analysis of patients with refractory urinary urge incontinence who underwent placement of a neuromodulator lead and generator was undertaken between October 2000 and December 2003. Quantitative assessment of the severity of their urinary leakage was assessed by preoperative and postoperative 3-day bladder diaries documenting leakage episodes, number of pads used per day, and a 24-hour pad weight assessment. Cure was defined as no daily leakage episodes after permanent implantation. Subjective outcome was assessed using the Incontinence Impact Questionnaire. Two-sample independent t tests, two-way chi-square tests, and tests of two proportions were performed when appropriate, with P < 0.05 considered significant.
RESULTS: The mean postimplantation follow-up was 29 months, and the average age was 60 years (range 29 to 83). The cure rate was associated with age, with individuals younger than 55 years having a statistically significant greater cure rate (65% versus 37% for older individuals; P < 0.05). Having three or more chronic conditions was associated with a lower cure rate in both younger and older individuals. Patients with a neurologic condition also had a lower cure rate, but no specific neurologic condition was associated.
CONCLUSIONS: Age older than 55 years and more than three chronic conditions were independent factors associated with a lower cure rate in patients implanted with a sacral neuromodulator for refractory urge incontinence. A neurologic condition may be associated with a decrease in the cure rate.

Entities:  

Mesh:

Year:  2005        PMID: 16230129     DOI: 10.1016/j.urology.2005.04.031

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  36 in total

Review 1.  A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction.

Authors:  Ash K Monga; Michael R Tracey; Jeyakumar Subbaroyan
Journal:  Int Urogynecol J       Date:  2012-03-17       Impact factor: 2.894

Review 2.  Sacral neuromodulation for lower urinary tract dysfunction.

Authors:  Philip E V Van Kerrebroeck; Tom A T Marcelissen
Journal:  World J Urol       Date:  2011-10-12       Impact factor: 4.226

Review 3.  Current opinion: complications and troubleshooting of sacral neuromodulation.

Authors:  Paul Pettit
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 4.  Sacral nerve stimulation in the elderly.

Authors:  Tomas L Griebling
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 5.  Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain.

Authors:  Robert D Mayer; Fred M Howard
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 6.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

7.  Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.

Authors:  Holly E Richter; C L Amundsen; S W Erickson; J E Jelovsek; Y Komesu; C Chermansky; H S Harvie; M Albo; D Myers; W T Gregory; D Wallace
Journal:  J Urol       Date:  2017-05-10       Impact factor: 7.450

Review 8.  [The future of invasive neuromodulation: new techniques and expanded indications].

Authors:  A van Ophoven; J Pannek
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

9.  Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability.

Authors:  Tanya Davis; Iryna Makovey; Michael L Guralnick; R Corey O'Connor
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

10.  Neuromodulation versus medication for overactive bladder: the case for early intervention.

Authors:  Frank N Burks; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.